Advertisement


Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement



Oct
03
Today In Oncology
Relapsed or Refractory Multiple Myeloma Mezigdomide Plus Dexamethasone
Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
Prophylactic Radiation for High-Risk Asymptomatic Bone Metastases
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside